K A Marrone - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

K A Marrone

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Clinical Pharmacology and Therapeutics|May 13, 2016

Immune-Related Adverse Events From Immune Checkpoint InhibitorsK A Marrone, W Ying, J Naidoo

ESMO Open|December 10, 2023

Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasisK Liang, J L Feliciano, K A Marrone, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Clinical Pharmacology and Therapeutics|May 13, 2016

Immune-Related Adverse Events From Immune Checkpoint InhibitorsK A Marrone, W Ying, J Naidoo

ESMO Open|December 10, 2023

Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasisK Liang, J L Feliciano, K A Marrone, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARDJ W Riess, H A Yu, X Le, et al.

Pageof 1